Filgotinib (JAK1i) | PharmaShots

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for

Vartika Singh September 6, 2018

Shots: The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for 12 wks. TORTUGA results (N=116): improvement in AS disease, ASAS20 response (76% vs 40%), ASDAS (-1.5 vs -0.6) with no new safety signals and deaths […]Read More

Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations

Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases

AbbVie and Calico Expand its Existing Collaboration to Focus on Aging and Age-Related Diseases

Viatris and Biocon’s Semglee (biosimilar, insulin glargine) Receive the US FDA’s Approval as the First Interchangeable Biosimilar for Diabetes

Meiji and Dong-A ST Sign an Exclusive License Agreement with Intas to Commercialize DMB-3115, Proposed Biosimilar to Ustekinumab

Adagio Collaborates with Biocon to Provide COVID-19 Ab Treatment to Patients in India and Other Emerging Markets

Celltrion Collaborates with Inhalon to Develop Regdanvimab (CT-P59) for the Treatment of COVID-19 at Home

Takeda’s TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1

Roche Reports the US FDA’s Acceptance of BLA for Faricimab to Treat Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria

BridgeBio Enters into Clinical Collaboration with BMS to Evaluate BBP-398 + Opdivo for Advanced Solid Tumors with KRAS Mutations

Tags : Filgotinib (JAK1i)

Gilead and Galapagos NV’s Filgotinib (JAK1i) Achieves Primary Endpoints for

Latest Posts

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras

Takeda’s TAK-994 Receives Breakthrough Therapy Designation for the Treatment of Narcolepsy Type 1

Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

Viatris and Biocon’s Semglee (biosimilar, insulin glargine) Receive the US FDA’s Approval as the First Interchangeable Biosimilar for Diabetes

Tags : Filgotinib (JAK1i)

Latest Posts

Categories

Related Topics